| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V122172 | (S)-HDAC-IN-102 | 748159-43-5 | (S)-HDAC-IN-102 is an HDAC8 inhibitor and an isomer of HDAC-IN-102. |
|
V4087 | UF010 | 537672-41-6 | UF010 (UF-010; UF 010) is a novel, potent and selective class I HDAC inhibitor with potential anticancer activities. |
|
V0284 | Sodium Phenylbutyrate (4-PBA sodium) | 1716-12-7 | Sodium phenylbutyrate (4-Phenylbutyric acid sodium; 4-PBA sodium),an orphan drug marketed by Ucyclyd Pharma, is a novel and potent histone deacetylase (HDAC) inhibitor used as an as adjunctive therapy for chronic treatment of urea cycle disorders involving deficiencies of argininosuccinic acid synthetase (AS), ornithine transcarbamylase (OTC), or carbamylphosphate synthetase (CPS). |
|
V0264 | Domatinostat (4SC202) | 910462-43-0 | Domatinostat (formerly 4SC-202)is a novel, potent, and orally bioavailable benzamide-based Class I HDAC inhibitor with potential anticancer activity. |
|
V97450 | Acefylline piperazine | 18833-13-1 | Acetylphylline piperazine is a xanthine derivative and adenosine receptor antagonist. |
|
V2907 | ACY-738 | 1375465-91-0 | ACY-738 (ACY738) is a novel, potent, selective, brain penetrable and orally-bioavailable HDAC6 inhibitor with neuroprotective and anticancer activities. |
|
V0283 | AR-42 (HDAC-42, NSC-736012, OSU-42) | 935881-37-1 | AR-42 (HDAC-42, NSC-736012, OSU-42 etc.) is a novel and potent histone deacetylase (HDAC) inhibitor with potential antitumor activity. At 30 nM, its IC50 inhibits HDAC. |
|
V0262 | BG45 | 926259-99-6 | BG45 (BG-45) is a novel, potent and selective class I HDAC inhibitor with potential anticancer activity. |
|
V0263 | BRD73954 | 1440209-96-0 | BRD73954 (BRD-73954) is a novel, potent and dual inhibitor of histone deacetylase 6 (HDAC6) and HDAC8 with potential anticancer activity. |
|
V0267 | CAY10603 | 1045792-66-2 | CAY10603 is a novel, potent and selective HDAC6 (Histone deacetylase) inhibitor with potential anticancer activity and a potential to treatneurodegenerative diseases. |
|
V2867 | CAY10683 (Santacruzamate A) | 1477949-42-0 | Santacruzamate A (also known as CAY10683) is a potent and selective inhibitor of HDAC (histone deacetylase) with IC50 of 119 pM for HDAC2, it exhibits >3600-fold selectivity over other HDACs. |
|
V0277 | CUDC-101 | 1012054-59-9 | CUDC-101 is a novel, potent and multi-targeted histone deacetylase (HDAC) inhibitor with potential anticancer activity. |
|
V88739 | DLC-50 | 2928537-98-6 | DLC-50 is a dual inhibitor of PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM, respectively. |
|
V96662 | DNMT1/HDAC-IN-1 | DNMT1/HDAC-IN-1 (Compound (R)-23a) is a DNMT1/HDAC dual inhibitor (HDAC1: IC50=0.05 μM), HDAC1 is a major HDAC isoform that interacts with DNMT1 in multiple protein complexes to silence the transcription of TSGs. | |
|
V3844 | Givinostat HCl | 199657-29-9 | Givinostat (ITF-2357 hydrochloride)is a potent andorally bioactive HDAC inhibitor with potential anti-inflammatory, anti-angiogenic, and anticancer activities. |
|
V88675 | HDAC-IN-72 | 763066-77-9 | HDAC-IN-72 (compound 7j) is a potent HDAC1 (IC50=0.65 μM), HDAC2 (IC50=0.78 μM), HDAC3 (IC50=1.70 μM) inhibitor and antiproliferative compound. |
|
V118306 | HDAC-IN-93 | HDAC-IN-93 is an HDAC inhibitor with good pan-HDAC inhibitory activity. | |
|
V109166 | HDAC/HSP90-IN-1 | 2244714-37-0 | HDAC/HSP90-IN-1 (compound 20) is a potent dual inhibitor of HDAC (IC50 = 194 nM) and HSP90 (HSP90α IC50 = 153 nM). |
|
V137170 | HDAC/PSMD14-IN-1 | 3062141-62-9 | HDAC/PSMD14-IN-1 is a thiorutin derivative. |
|
V109219 | HDAC1-IN-12 | HDAC1-IN-12 is an inhibitor of Plasmodium falciparum HDAC1 (PfHDAC1) with an IC50 value of 4.1 nM. |